Skip to content

Author

Tian-Tian You

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Do progression-free survival benefits justify increased toxicity and treatment burden? A meta-regression analysis of phase III immune checkpoint inhibitor trials from a value-based oncology perspective.

PFS showed a limited and treatment-type-dependent association with OS, and PFS gains frequently accompanied increased toxicity.

Zhen-Yang Long, Tian-Tian You, Yu-Qi Zhao · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.